$2.9 Billion Interventional Oncology Market by Product, Procedures, Cancer - Global Forecast to 2024 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Mar 21, 2019--The “Interventional Oncology Market by Product, Procedures, Cancer - Global Forecast to 2024” report has been added to ResearchAndMarkets.com’s offering.
The global interventional oncology market is projected to reach USD 2.9 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 6.8% from 2019 to 2024.
The growth of this market is primarily driven by the rising preference for minimally invasive procedures, expansion of the target patient population, increasing public-private funding and government support for cancer research, technological advancements in the field of interventional oncology, and increasing government investments and funding for interventional oncology and related cancer research. However, the dearth of well-trained and skilled radiologists and oncologists, high costs of interventional oncology procedures, and unfavorable regulations are expected to limit market growth to a certain extent.
The transcatheter arterial radioembolization TARE or selective internal radiation therapy SIRT segment accounted for the largest share of the global interventional oncology market during the forecast period
On the basis of procedure, the interventional oncology market is segmented into thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization TACE, transcatheter arterial radioembolization TARE or selective internal radiation therapy SIRT, and transcatheter arterial embolization TAE or bland embolization procedures. In 2018, the TARE/SIRT procedures segment accounted for the largest share of this market majorly due to the rising prevalence of cancer, increasing demand for minimally invasive procedures, growing adoption of embolization procedures, and the clinical efficacy of Yttrium-90 radioembolic agents which are used in these procedures.
The liver cancer segment accounted for the largest share of the interventional oncology market during the forecast period
Based on cancer type, the interventional oncology market is segmented into liver cancer, lung cancer, kidney cancer, bone cancer, and other cancers. The other cancers segment includes pediatric cancer, prostate cancer, and breast cancer. The liver cancer segment accounted for the largest share in the interventional oncology market in 2018.
Europe accounted for the second-largest share of the global market in 2018
The interventional oncology market is segmented into five major regions, namely North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Europe accounted for the second-largest share in 2018. The rising incidence of cancer, coupled with the growing geriatric population in Europe, is a key factor propelling the demand for interventional oncology products in this region.
Prominent market players are focusing on improving the quality of patient care across Europe by commercializing advanced products, investing in technological innovations, and partnering with other institutions and organizations for spreading cancer awareness. This is another major factor driving market growth.
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Interventional Oncology: Market Overview
4.2 Geographic Analysis: Interventional Oncology Market, By Product
4.3 Asia Pacific: Ablation Devices Market, By Type (2018)
4.4 Europe: Interventional Oncology Market, By Cancer Type (2018)
4.5 Interventional Oncology Market, By Procedure, 2019 vs 2024 (USD Million)
4.6 Geographical Snapshot of the Interventional Oncology Market
5 Market Overview
5.2 Market Dynamics
18.104.22.168 Rising Patient Preference for Minimally Invasive Procedures
22.214.171.124 Expansion of the Target Patient Population
126.96.36.199 Increasing Public-Private Funding and Government Support for Interventional Oncology
188.8.131.52 Technological Advancements in Interventional Oncology
184.108.40.206 Dearth of Well-Trained and Skilled Radiologists and Oncologists
220.127.116.11 Unfavorable Regulations
18.104.22.168 Emerging Economies Offer High Growth Potential
22.214.171.124 Rising Awareness About the Benefits of Interventional Oncology
126.96.36.199 Limited Clinical Data to Support Therapeutic Efficacy
188.8.131.52 Strong Market Positioning of Alternative Therapies
5.3 Market Trends
5.3.1 Personalized Or Precision Interventional Oncology
6 Interventional Oncology Market, By Product
6.2 Embolization Devices
6.2.1 Interventional Oncology Embolization Devices Market Split, By Procedure
6.2.2 Interventional Oncology Embolization Devices Market Split, By Cancer Type
6.2.3 Radioembolic Agents
6.2.4 Non-Radioactive Embolic Agents
6.3 Ablation Devices
6.3.1 Technological Advancements in Ablation DevicesA Key Driver for Market Growth
6.3.2 Radiofrequency (RF) Ablation Devices
6.3.3 Microwave Ablation Devices
6.3.4 Cryoablation Devices
6.3.5 Other Ablation Devices
6.4 Support Devices
6.4.1 Interventional Oncology Support Devices Market Split, By Procedure
6.4.2 Interventional Oncology Support Devices Market Split, By Cancer Type
184.108.40.206.1 Guidewires Market Split, By Procedure
220.127.116.11.2 Guidewires Market Split, By Cancer Type
7 Interventional Oncology Market, By Procedure
7.2 Thermal Tumor Ablation
7.2.1 Increasing Clinical Evidence is A Major Factor Driving Market Growth
7.3 Non-Thermal Tumor Ablation
7.3.1 Nanoknife has Emerged as A Potential Alternative to Thermal Tumor Ablation Techniques
7.4 Transcatheter Arterial Chemoembolization
7.4.1 Ability to Treat Small and Large-Sized Tumors - A Major Factor Driving the Demand for Tace Procedures
7.5 Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
7.5.1 Tare Shows Greater Clinical Efficacy as Compared to Tace
7.6 Transcatheter Arterial Embolization/Bland Embolization
7.6.1 Increasing Clinical Evidence for Tare and Tace to Restrain Growth of This Market
8 Interventional Oncology Market, By Cancer Type
8.1.1 Liver Cancer
18.104.22.168 Increasing Disease Prevalence and Rising Research Activity are Driving Market Growth
8.1.2 Lung Cancer
22.214.171.124 Increasing Number of Cancer Cases Will Drive the Demand for Interventional Oncology Procedures
8.1.3 Bone Cancer
126.96.36.199 Interventional Oncology Procedures Can Eliminate Tumors Directly and Relieve Pain
8.1.4 Kidney Cancer
188.8.131.52 Interventional Oncology Procedures are Appropriate for Patients With A Genetic Disposition for Multiple Tumors
8.1.5 Other Cancers
9 Interventional Oncology Market, By Region
9.2 North America
184.108.40.206 US to Dominate the North American Interventional Oncology Market
220.127.116.11 Public-Private Initiatives to Support the Adoption of Interventional Oncology Procedures in Canada
18.104.22.168 Germany is the Fastest-Growing Market in Europe
22.214.171.124 Increasing Awareness and Support for Cancer-Related Activities to Drive Market Growth in the UK
126.96.36.199 Radiofrequency Ablation Dominated the Ablation Devices Market in France
9.3.4 Rest of Europe
9.4 Asia Pacific
188.8.131.52 Rising Geriatric Population and Universal Healthcare Reimbursement are the Major Driving Factors
184.108.40.206 Increasing Cancer Incidence and Growing Patient Population to Drive Market Growth in China
220.127.116.11 Improving Research Capabilities Coupled With the Expansion of Key Players to Drive Market Growth in India
9.4.4 Rest of Asia Pacific
9.5 Latin America
18.104.22.168 Brazil to Account for the Largest Share of the Latin American Interventional Oncology Market
22.214.171.124 Growing Awareness Campaigns and Rising Incidence of Cancer to Drive Market Growth in Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Improving Healthcare Infrastructure and Rising Incidence of Cancer are Driving Growth in the Middle East and Africa
10 Competitive Landscape
10.2 Global Market Share Analysis, 2017
10.3 Competitive Scenario (2015 - 2019)
10.4 Vendor Dive Overview
10.5 Vendor Inclusion Criteria
10.6 Vendor Dive
11 Company Profiles
11.1 Healthtronics, Inc.
11.2 Trod Medical
11.3 Sanarus Technologies, Inc.
11.4 Teleflex, Inc.
11.5 Imbiotechnologies Ltd.
11.6 Medwaves, Inc.
11.7 Icecure Medical
11.8 Terumo Corporation
11.9 Medtronic PLC
11.10 BTG PLC
11.11 Johnson & Johnson
11.12 Merit Medical Systems, Inc.
11.13 Boston Scientific Corporation
11.14 Angiodynamics, Inc.
11.15 Cook Medical
For more information about this report visit https://www.researchandmarkets.com/research/ftjt93/2_9_billion?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190321005436/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH ONCOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 03/21/2019 10:00 AM/DISC: 03/21/2019 10:00 AM